# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

Docket No. 428.1014

Total Pages in this Submiss

	(Small Entity)	Total Pages III tills
	(Small Efficiency)  (Only for new nonprovisional applications under 37 CFR 1.53(b))	
ي ي ي	(Only for new nonprovisional approved TO THE ASSISTANT COMMISSIONER FOR PATENT Pay Patent Application	115
P	TO THE ASSISTANT Control of the Assistant Application Washington, D.C. 20231	
ď	and a second sec	vutility patent application for an
٠.	horewith for filing under 35 U.S.C. 111(a) and	RY SUBSTITUTING ONE OR
inventio	tted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.35(a) is a nentitled:  EL PEPTIDES WITH INCREASED + CHARGE AND HYDROPHOBICITY IN ACIDS OF CA-MA PEPTIDE AND PHARMACEUTICAL COMPONENTS AND ACIDS OF CA-MA PEPTIDE AND PHARMACEUTICAL COMPONENTS AND ACIDS OF CA-MA PEPTIDE AND PHARMACEUTICAL COMPONENTS AND PROPERTY OF CA-MA PEPTIDE AND PHARMACEUTICAL COMPONENTS AND PHARMACEUTICAL COMPO	OSITIONS CONTAINING
NOV	n entitled: EL PEPTIDES WITH INCREASED + CHARGE AND HYDROPHOBICITY I EL PEPTIDES WITH INCREASED + CHARGE AND HYDROPHOBICITY I EL AMINO ACIDS OF CA-MA PEPTIDE ANDPHARMACEUTICAL COMP	
THE	REOF	
	and by:	
and inv	rented by: ng - Soo HAHM, Dong Gun LEE, Yoon Kyung PARK, and Hee Nam KIM	
Kyu		
	and cupply the requ	isite information:
1	CONTINUATION APPLICATION, check appropriate box and supply the requ	r application No.:
Ifac	Divisional —	
1	ch is a:  Divisional Continuation-in-part (CIP) of price	or application No.:
	Continuation   Divisional   Continuation   Divisional	
1	Continuation   Continuation   Divisional   Continuation   Divisional   Continuation	or application No.:
1	Continuation   Divisional Continuation part	
En	closed are: Application Elements	•
	without as described below	
	1. X Filing fee as calculated and transmitted as described below	the following:
	<ol> <li>Specification having</li></ol>	ing the lollowing.
Ţ	2. Specification having	
1		
	a.   Descriptive Title of the Invention  (familicable)	
	A ligations (If applicable)	oment (if applicable)
	b. Cross References to Related Applications (if applicable)	pment (if applicable)
	b. Cross References to Related Applications (if applicable)	opment <i>(if applicable)</i> gram Listing Appendix
	<ul> <li>b.</li></ul>	opment (if applicable) gram Listing Appendix
	<ul> <li>b.</li></ul>	pment <i>(if applicable)</i> gram Listing Appendix
	<ul> <li>b.</li></ul>	opment <i>(if applicable)</i> gram Listing Appendix
	<ul> <li>b.</li></ul>	opment (if applicable) gram Listing Appendix
	<ul> <li>b.  Cross References to Related Applications (if applicable)</li> <li>c.  Statement Regarding Federally-sponsored Research/Develor</li> <li>d.  Reference to Sequence Listing, a Table, or a Computer Program Background of the Invention</li> <li>f.  Background of the Invention</li> <li>g.  Brief Description of the Drawings (if filed)</li> </ul>	opment <i>(if applicable)</i> gram Listing Appendix
	<ul> <li>b.</li></ul>	pment (if applicable) gram Listing Appendix
	<ul> <li>b.  Cross References to Related Applications (if applicable)</li> <li>c.  Statement Regarding Federally-sponsored Research/Develor</li> <li>d.  Reference to Sequence Listing, a Table, or a Computer Program Background of the Invention</li> <li>f.  Background of the Invention</li> <li>g.  Brief Description of the Drawings (if filed)</li> </ul>	opment (if applicable) gram Listing Appendix

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 428.1014

Total Pages in this Submission

## UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

was unintentional.

Docket No. 428.1014

Total Pages in this Submission

	( · · · · · · · · · · · · · · · · · · ·
_	Accompanying Application Parts (Continued)
	17. Applicant claims small entity status. See 37 CFR 1.27.  ☑ (Optional) Small Entity Statement(s) - Specify Number of Statements Submitted:
	17.  Additional Enclosures (please identify below):
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.  Warning
	yvaining
	An applicant who makes a request not to publish, but who subsequently files in a foreign An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(i), country or under a multilateral international agreement specif

within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice

# UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 428.1014

Total Pages in this Submission

### Fee Calculation and Transmittal

		CLAIMS AS FILED			Fee	
	ur:led	#Allowed	#Extra	Rate		\$0.00
For	#Filed	- 20 =	0	x \$9.00		\$0.00
otal Claims	8	- 3 =	0	x \$42.0	0	\$0.00
ndep. Claims	1 (abov	k if applicable)			BASIC FEE	\$370.00
Multiple Dependent Claims (check if applicable)  BASIC FEE						\$0.00
OTHER FEE (sp	ecify purpose)			TO	OTAL FILING FEE	\$370.00

to cover the filing fee is enclosed. ▼ The Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0217 ☐ A check in the amount of

as described below. A duplicate copy of this sheet is enclosed.

Charge the amount of

 ★ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. ☑ Credit any overpayment.

☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance,

pursuant to 37 C.F.R. 1.311(b).

Dated: February 22, 2002

Michael N. Mercanti ROBERTS & MERCANTI, LLP

P.O. Box 3156 105 Lock Street

Suite 203

Newark, NJ 07103 973 621 0660 973 621 0774 (fax)

CC:

PATENT TRADIENTARY OFFICE

022856

Page 4 of 4

P01USML/REV05

### 

	AIL BY "EXPRESS M	AIL" (37 CFR 1.15)	428.1014
Serial No. to be assigned  NOVEL PEP	Filing Date Feb 22, 2002	Examiner  to be assigned  HARGE AND HYDROPHOBICIT  TIDE ANDPHARMACEUTICAL C	Group Art Unit to be assigned Y BY SUBSTITUTING ONE COMPOSITIONS
Patent Application 36	e following correspondence:  pages, 6 sheets of drawings  (Identify type)	e of correspondence)	Addressee" service under
37 CFR 1.10 in an el	ith the United States Postal Sernivelope addressed to: The Assistance <b>y 22, 2002</b>	e of correspondence) vice "Express Mail Post Office to stant Commissioner for Patents, V  Michael N. Me	oveanti
( <i>D</i>		Michael N. IVI	Tailing Correspondence)

Note: Each paper must have its own certificate of mailing.